Chargepoint Technology

Chargepoint Technology

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11.2M

Overview

Chargepoint Technology is a specialized provider of engineering solutions for aseptic processing in the life sciences industry. Founded in 1993, the company has established itself as a leader in containment and transfer technology, crucial for the manufacture of sterile injectables, biologics, and potent compounds. Its products are integral to ensuring regulatory compliance, operator safety, and product protection in GMP environments. The company operates in a stable, niche market driven by stringent regulatory standards and the growth of complex biopharmaceuticals.

Drug Delivery

Technology Platform

Hardware and engineering platform for aseptic transfer and containment, featuring proprietary valve systems for sterile and safe material transfer in pharmaceutical manufacturing.

Funding History

2
Total raised:$11.2M
Series A$10M
Grant$1.2M

Opportunities

Growth is driven by the expansion of biologics and advanced therapies (cell/gene), which require stringent aseptic processing, and the increasing global adoption of single-use systems, creating a recurring consumables revenue stream.
Regulatory demands for higher containment in potent drug manufacturing also present a sustained market need.

Risk Factors

Risks include potential customer concentration with large pharma and CDMOs, intense competition from larger life science tools companies with broader portfolios, and the need for continuous innovation to avoid technological obsolescence in a rapidly evolving manufacturing landscape.

Competitive Landscape

Chargepoint competes in a niche segment with specialized peers and large, diversified life science tools companies like Sartorius, Cytiva (formerly part of GE), and Merck Millipore. Competition is based on technical performance, reliability, regulatory support, and deep integration into customer processes rather than price alone.